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Abstract
Spinal cord injury (SCI) results into an immediate primary injury (physical 
damages) followed by secondary damages (prolonged posttraumatic inflammatory 
disorder) resulting into severe motor dysfunction including paralysis. The present 
chapter discusses and investigates the neuroprotective effects of cyclosporin-A 
(CsA), minocycline, and tacrolimus (FK506) and their therapeutic effectiveness 
in recovery from the animal model of SCI. Based on the available recent literature 
on these three drugs, as well as in perspective of the results obtained on some 
experimental behavioral, biochemical, and oxidative stress parameters in the 
present study, the therapeutical potential of these three drugs has been discussed. 
Furthermore, the animal model of SCI used herein has been reviewed and com-
pared with other reported animal models for understanding the utility, suitability, 
and reproducibility of the methodology of the present model for screening purposes 
in quest of searching ideal therapeutic compounds for maximum recovery from SCI.
Keywords: cyclosporin-A, minocycline, tacrolimus (FK506), rats,  
spinal cord injury, behavior, oxidative stress
1. Introduction
Spinal cord injury (SCI) is prevalent worldwide [1, 2] and often incapacitates the 
victims for life resulting in disability. Injury to the spinal cord results in processes 
that occur in three phases: the first phase is immediate physical phase also known as 
acute phase comprising affected spinal shock and initial trauma (primary injury) 
followed by the second phase known as secondary phase which is a prolonged 
cascade of damaging processes over a time period of minutes to weeks after the 
injury (secondary injury). Such damages include ischemia, vascular alterations, 
biochemical alterations, and cellular responses that lead to peripheral posttraumatic 
inflammatory cell infiltration and cell death (secondary injury) [1, 3–5]. The third 
phase that sustains between days and years after SCI trauma is characterized by 
proapoptotic degeneration and scarring that establishes permanent functional 
impairment [6, 7]. Secondary injury leads to the key pathophysiological response 
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to SCI causing severe and permanent functional deficits. Most of the clinical trials 
and experimental studies are conducted for intense research to unfold the underly-
ing pathophysiological processes and for searching ideal and potential therapy for 
recovery from secondary SCI injuries [8]. Besides motor dysfunction, some of the 
other important SCI-related biochemical and immunological impairments that get 
involved are serum tumor necrosis factor (TNF)-α, interleukin (IL)-1β, interleu-
kin-6, nuclear factor (NF)-κB p65, p38 mitogen-activated protein kinase (MAPK), 
inducible nitric oxide synthase (iNOS), caspase-3, superoxide dismutase (SOD), 
catalase (CAT), malondialdehyde (MDA), and glutathione peroxidase (GSH-Px) 
[9]. SCI trauma causes a devastating effect not only to the individual patient, but 
it also incurs heavy expensive burden to the society in general and to the family 
members, due to substantial long-term healthcare expenditures [10].
Despite considerable therapeutic studies, no proven drugs or techniques are 
available for satisfactory treatment of SCI. Much of these therapeutic studies have 
been reported from animal models, and it needs to be understood that a success-
ful clinical trial in humans can only be initiated based on previously available 
preclinical data reported from animal model studies that closely mimic the losses 
as in human SCI functions [11]. Although rats are the animal model of choice for 
SCI studies, the major anatomical differences in axonal tracts and sensory motor 
pathways between quadrupeds and bipeds need to be taken into careful account to 
improve the targets of human SCI treatments [12].
Currently, methylprednisolone is the only recognized treatment for human 
SCI; however, it has significant adverse effects, including respiratory complica-
tions, sepsis, and gastrointestinal hemorrhage [13]. Furthermore, other important 
evidence-based therapies that have potential neuroprotective and neural reparative 
therapeutic properties and are undergoing clinical trials for human SCI include sur-
gical decompression, blood pressure augmentation, riluzole, granulocyte colony-
stimulating factor, minocycline, glibenclamide, cerebrospinal fluid drainage, 
magnesium, therapeutic hypothermia, Cethrin (VX-210), anti-NOGO antibody, 
cell-based approaches, and bioengineered biomaterials [5, 14, 15].
Some other experimental drugs that have been studied for therapeutical use in 
animal SCI are recombinant human erythropoietin [10], tetrodotoxin [16], BCL-2 
[17], cyclosporin-A [18], edaravone [19], atorvastatin [20], calpain inhibitors [21] 
FK506, and minocycline [22]. Also, some natural products like eugenol oil [9], 
curcumin [23], and melatonin [24] have shown promising effects in animal SCI 
functional recovery. It sounds reasonable that instead of using a highly selective 
treatment that targets a specific molecule or pathway, a compound with multifunc-
tional properties that targets several mediators involved in spinal cord pathology 
may be more effective for recovery from SCI [25]. In our earlier study [22], the 
promising potential of FK506 and minocycline has been reported for their effec-
tiveness in rat SCI model. Thus, in the present study, besides these two multifacto-
rial effective compounds minocycline and FK506, a third compound cyclosporin-A 
(CsA) was also included, and all the three compounds minocycline, FK506 (tacro-
limus), and cyclosporine-A were chosen to evaluate in a comparative manner for 
their therapeutical potential using some important and reliable parameters that are 
most commonly used in rat SCI model [22]. Before discussing the outcome of our 
present results, we review the multifactorial effects of these three compounds that 
have been reported in literature using rat SCI model.
1.1 Minocycline
Minocycline, a semisynthetic second-generation tetracycline, has robust neuro-
protective effects in rodent models of neurodegenerative diseases [26] and provides 
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neuroprotection in experimental models of neurological diseases, including SCI 
[27]. In a broad range of secondary injury mechanisms via its anti-inflammatory, 
antioxidant, and antiapoptotic properties, minocycline is effective in reducing sec-
ondary injury and promoting locomotor functional recovery [28–31]. Minocycline 
prevents N-methyl-d-aspartate (NMDA)-induced excitotoxicity by diminishing 
NMDA-induced Ca2+ influx and mitochondrial Ca2+ uptake [32] and protects gray 
and white matter from SCI [33]. Minocycline also inhibits p38 mitogen-activated 
protein kinase (p38 MAPK) activation and microglial pro-nerve growth factor 
(proNGF) expression resulting from inflammatory reactions due to SCI and 
improves oligodendrocyte survival [34]. Inflammation due to SCI also upregulates 
and activates a class of enzymes like phospholipase A2s (PLA2s), and minocy-
cline reduces cPLA2s [35]. It also inhibits monocyte and microglial expression of 
cyclooxygenase 2 (COX2) and production of proinflammatory prostaglandins E2 
[36] and suppresses 5-lipoxygenase (5-LOX) action in SCI tissue [37]. Minocycline 
also eliminates free radicals in the post-SCI microenvironment and protects from 
oxidative stress [38]. It inhibits malondialdehyde, a by-product of lipid peroxida-
tion [39, 40], and increases glutathione (GSH) [39], superoxide dismutase, and 
glutathione peroxidase [40], suggesting the powerful antioxidative mechanisms 
of minocycline to recover from secondary injury in SCI. Minocycline is reported to 
inhibit matrix metalloproteinases (MMPs) that are upregulated following SCI and 
are involved in injury and recovery processes [41, 42]. Furthermore, minocycline 
improves functional outcome, reduces lesion size and cell death, and alters cytokine 
expression after SCI [43–45]. Minocycline reduces the lesion area, increases the 
number of descending sympathoexcitatory axons traversing the injury site, and 
ultimately reduces the severity of autonomic dysreflexia [46]. In a murine model 
of SCI, minocycline treatment was superior to methylprednisolone in promoting 
functional improvement [44] and had neuroprotective effects on the SCI epicenter 
[47], motor neuron recovery, and neuropathic pain [48]. Minocycline has recently 
been reported to be effective in reducing secondary injury and promoting locomo-
tor functional recovery in experimental SCI [28].
It has also been reported to attenuate reactive astrocytosis in SCI which directly 
damages cell bodies and triggers endogenous processes including neuroinflamma-
tion and reactive astrocytosis [49, 50]. In combination studies also, minocycline has 
been reported for better recovery from SCI when used in combination with other 
drugs like FK506 [22] and bone marrow mesenchymal cells (BMSCs) [51] showing 
a very significant recovery in behavioral function, oxidative stress, and reduction in 
lesion size from SCI in rats warranting further research on this drug.
1.2 Cyclosporin-A
Cyclosporin-A is an immunosuppressive cyclic undecapeptide that inhibits T 
cells and depresses both cellular and humoral immune responses to prevent graft 
rejection and reduces the inflammatory responses [52]. CsA significantly decreases 
the expression levels of interleukin-10, tumor necrosis factor-α, cyclophilin-D 
(Cyp-D), and apoptosis-inducing factor (AIF) [53]. CsA does not readily cross the 
blood-spinal cord barrier (BSCB), which restricts the clinical application of CsA 
for SCI treatment. Thus, polyethylene glycol (PEG)-transactivating-transduction 
protein (TAT)-modified CsA-loaded cationic multifunctional polymeric liposome-
poly (lactic-co-glycolic acid) (PLGA) core/shell nanoparticles (PLGA/CsA NPs) to 
transport and deliver CsA across the BSCB have a new potential to treat SCI [54]. 
CsA inhibits primarily the inflammatory reaction and the synthesis of constitutive 
nitric oxide (NO) and inducible nitric oxide synthases (NOS), well-known neuro-
toxic agents for SCI diminishing overproduction of free radicals, and secondarily 
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lipid peroxidation (LP) observed after SCI [55, 56]. CsA may also induce other 
non-immunological effects that could be beneficial for treatment of neurologi-
cal disorders [57]. CsA has been widely used in the treatment of various diseases 
including aplastic anemia, nephritic syndrome, rheumatoid arthritis, psoriasis, and 
cerebral ischemic injuries [53]. CsA promotes neuroprotection by diminishing both 
demyelination and neuronal cell death, resulting in a better motor outcome after 
SCI [52, 58, 59]. CsA in combination with FK506 had a neuroprotective treatment 
against SCI hypoxia-induced damage mediated via their antioxidant actions on 
mitochondrial ATP, tissue-reduced glutathione, tissue LPO level, and myeloper-
oxidase (MPO) activity [60]. Administration of CsA in combination with olfactory 
ensheathing cell (OEC) transplantation results in augmented functional improve-
ments and promotes axon regeneration after SCI [61].
1.3 FK506
FK506 (tacrolimus), a macrolide lactane antibiotic, was introduced as an 
immunosuppressive agent [62] with virtually no side effects [63]. FK506, a potent 
calcineurin inhibitor, exhibits neuroprotective actions in several experimental mod-
els of central nervous system trauma, including stroke, and improved neurological 
recovery following peripheral and spinal cord injuries [47, 63–67]. It is reported that 
FK506 has beneficial effects in SCI recovery involving various mechanisms such as 
neuroregeneration and neuroprotection [67], promotion of axonal outgrowth [68], 
and suppression of oxidative stress [60]. FK506 improves the functional outcome of 
SCI [67–69] and has an in vivo neurotrophic action, whereby it enhances the rate of 
axon regeneration, leading to more rapid neurological recovery [70–73]. Significant 
functional recovery from SCI due to FK506 treatment has been reported in rat 
models [22, 67, 74]. Activation of NF-κB and proinflammatory cytokines (TNF-a, 
IL-1b, and IL-6) expression levels in SCI animals is reversed by FK506 treatment 
involving microglial activation after SCI [7]. FK506 upregulates epidermal growth 
factor (EGF)-level expression of astrocytes that have an important role as mediators 
for SCI functional recovery promoting axonal regeneration [74]. FK506 in combi-
nation as a cocktail with other drugs like minocycline [22], CSA [60], RhoA inhibi-
tors [75], nerve growth factor (NFG) [76], and methylprednisolone (MP) [77] has 
shown significant therapeutic recovery from SCI in rats.
Considering the above-discussed multifactorial effects of CsA, minocycline, and 
FK506, the present study was undertaken to investigate the neuroprotective effects 
of these three compounds in a comparative manner on recovery from experimental 
SCI, as these three drugs target multiple processes involved in mediating cell death 
and the development of secondary injury in SCI. Furthermore, our earlier findings 
on FK506 and minocycline [22] prompted us to include CsA (another promising 
drug for SCI recovery) and compare their effectiveness in rat model of SCI, using 
the behavioral and biochemical parameters as in earlier [22].
2. Utility of experimental animal models for SCI studies
For SCI studies, animal models are used because of their easy accessibility, 
convenience, and capability of the researchers to explore them at several levels 
(simulated to human clinical SCI levels) for motor functional, biochemical, and 
oxidative stress and genetic, therapeutic, and pathophysiological evaluations [78]. 
Over the last decade, a variety of animal models have been used for experimental 
SCI studies, including rats, mice, gerbils, guinea pigs, hamsters, rabbits, dogs, 
goats, pigs, and nonhuman primates [79]. Among these animals, rodents in general 
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and rats in particular are the most widely and commonly studied SCI models [80]. 
In the present study also, we have used young adult male Sprague-Dawley rats with 
all similar specifications of breeding, housing facilities, and experimental han-
dlings, as described in our earlier study [22].
To establish an ideal SCI animal model for research purposes, various models have 
been tried and reported till to date in quest of searching methodology to obtain maxi-
mum recovery from SCI. These experimental animal models include spinal cord trau-
matic injury model [81], photochemical-induced SCI model [82], spinal cord transection 
model [83], bidirectional distraction SCI model [84], and the spinal cord ischemia-
reperfusion injury model [85]. For traumatic injury model, the contusive SCI model is 
used by inducing contusion on the dorsal spinal cord by dropping a desired weight either 
from a computer-controlled impact device [86] or from a customized impact device [87]. 
Another traumatic injury model known as compressive SCI model is also very com-
monly used where instead of dropping the weight, it is placed on the exposed spinal cord 
segment in the dorsoventral direction to induce a compressive SCI [88, 89]. However, 
since SCI caused by impact and compression is more common in clinical patients [79], 
in the present study also, we have used the compressed SCI model induced in the rats as 
described in our earlier study [22]. Briefly, the SCI was induced in the rats following the 
modified method of Nystrom and Berglund [89]. Laminectomy was performed at the T 
7–8 level, and spinal cord compression injury was produced by placing a load with a total 
weight of 35 g, for 5 min over the exposed extradural area.
All experimental rats were randomly divided into the following six groups with 
eight animals in each as described earlier [22]:
Group I: The normal control group without laminectomy or compression injury
Group II: Sham group with laminectomy alone but no spinal compression injury
Group III: SCI control group with laminectomy and spinal compression injury
SCI-treated groups were the same as the SCI control group (Group III) and 
consisted of three groups in which the effect on the recovery from SCI using the 
same parameters is mentioned in our earlier study [22]. Doses of the three drugs 
CSA, minocycline, and FK506 were selected on the basis of our pilot screening of 
these drugs at low, medium, and high doses, and the best effective dose in each was 
used in the present study as follows:
Group IV: Cyclosporin-A 5 mg/kg
Group V: Minocycline 50 mg/kg
Group VI: FK506 (tacrolimus) 1 mg/kg
All protocols for the drug administration, follow-ups, care, and experimental 
handlings of the animals for various evaluation parameters were the same as 
described earlier [22].
3. Behavioral evaluations in SCI animals
To analyze the therapeutic recovery from induced SCI in animal models, several 
behavioral outcome measures have been developed and widely used, such as the 
catwalk [90], the Basso-Beattie-Bresnahan (BBB) locomotor scale [91], the horizontal 
ladder test, and the cylinder rearing test [92]. From the literature review of the recent 
years, it is found that BBB locomotor scale has been most widely used in SCI rat  
models to evaluate motor functional recovery from SCI [9, 12, 22–24, 53, 58, 74, 77, 93].  
However, in the present study, besides BBB locomotor scale [94], a battery of some 
more behavioral motor functions was included like Tarlov scoring [95], inclined plane 
test [96], and some functional deficit scorings like toe spread, platform hang, wire 
mesh descent, and hind foot bar grab [97, 98]. Our pilot study showed that a naive 
control group of animals treated with CsA, minocycline, and FK506 without SCI 
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showed no different behaviors than the naïve control untreated groups (data not shown 
in behavioral results) for all the observed behavioral parameters. Thus, the results of 
the drug treatments alone were not included in all behavioral results (Figures 1–4). 
Figure 2. 
The effect of cyclosporin-A, FK506, and minocycline on the behavioral motor performance activity (Tarlov’s 
Score) of hind limbs of rats subjected to SCI. The graph shows the comparative functional recovery from SCI 
over a period of 29 days. Animals were treated with drugs daily after SCI for 3 weeks. Abbreviations, drugs 
used and their doses, and all statistical significances are the same as in Figure 1.
Figure 3. 
The effect of cyclosporin-A, FK506, and minocycline on the behavioral motor performance activity (Inclined 
Plane Test) of hind limbs (HL) of rats subjected to SCI. The graph shows the comparative functional recovery 
from SCI over a period of 29 days. Animals were treated with drugs daily after SCI for 3 weeks. Abbreviations, 
drugs used and their doses, and all statistical significances are the same as in Figure 1.
Figure 1. 
Effect of CSA, FK506, and minocycline on gait performance tunnel (GPT) behavioral motor performance 
activities (BBB Score) of hind limbs of rats subjected to SCI. The graph shows the comparative functional 
recovery from SCI over a period of 29 days. Animals were treated with the drugs daily after SCI for 3 weeks. 
Abbreviations: CSA, cyclosporin-A; FK506, tacrolimus; SCI, spinal cord injury; BBB, Basso, Beattie, and 
Bresnahan. Drug doses used are cyclosporin (5 mg/kg), FK506 (1 mg/kg), and minocycline (50 mg/kg); the 
drugs are effective in the order FK506 > minocycline > cyclosporin-A. # shows the SCI group is significantly 
(p < 0.001) different from the SCI uninjured control group. *, **, and *** represent the SCI-treated groups are 
significantly different at p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the SCI group by ANOVA 
with post hoc testing using Tukey-Kramer or Student-Newman-Keuls Multiple Comparison Tests.
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The present results of behavioral observations indicated that treatment with all the 
three drugs in this study induced significant recovery from SCI with respect to time in 
all behavioral activities compared to the SCI control group, and the drugs were effec-
tive in the order of FK506 > minocycline > CsA (F = 13.49, F = 5.82, and F = 3.14; df = 3; 
p < 0.001, p < 0.01, and p < 0.05, respectively) throughout (Figures 1–4).
4. Biochemical evaluations in SCI animal models
Biochemical evaluations have a vast list of parameters that exist as biomarkers 
for assessing recovery from SCI in animal models. Some of the most important 
biochemical parameters include oxidative stress indices like lipid peroxidation 
and total glutathione, nitric oxide synthase, myeloperoxidase, mitochondrial 
permeability, inflammatory responses, autonomic dysreflexia, cerebrospinal fluid 
biomarkers, immune responses, astrocyte modulations, etc., and all of these have 
been reviewed in detail earlier in this chapter, especially for the three drugs, CsA, 
minocycline, and FK506, that have been evaluated in the present study.
The biochemical parameters evaluated in this study included determination of 
monoamines 5-hydroxy-indoleacetic acid (5-HIAA) and serotonin or 5-hydroxy 
Figure 4. 
(A–D) The effect of cyclosporin-A, FK506, and minocycline on the behavioral motor functional scoring of 
toe spread (A), platform hanging (B), hind foot bar grab (C), and wire mesh decent (D) of rats subjected to 
SCI. The graph shows the comparative functional recovery from SCI over a period of 29 days. Animals were 
treated with drugs daily after SCI for 3 weeks. Abbreviations, drugs used and their doses, and all statistical 
significances are the same as in Figure 1.
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tryptamine (5-HT) [99], lipid peroxides determined as thiobarbituric acid-reactive 
substances (TBARS) [100, 101], total glutathione [102, 103], and myeloperoxidase 
[104] and have been described for their methods in our earlier study [22].
The present biochemical results showed significant ameliorating effect of all three 
drugs on the levels of 5-HT (Figure 5A, 5-HIAA; Figure 5B, on the ratio of 5-HIAA; 
and Figure 5C, 5-HT). TBARS was significantly stimulated (Figure 6A), whereas 
GSH was significantly inhibited (Figure 6B), and MPO level was significantly 
diminished toward the normal level (Figure 6C). Overall, the entire biochemical 
parameters evaluated in the present study were significantly affected by the three 
drugs effectively in the order FK506 > minocycline > CsA throughout.
Figure 5. 
(A–C) Levels of (A) 5-HT (5-hydroxytryptamine), (B) 5-HIAA (5-hydroxy-indoleacetic acid), and (C) the ratio 
of 5-HIAA and 5-HT activities in the spinal cord tissue of rats 29 days post-SCI and the effects of treatment with 
various drugs. Abbreviations, drugs used and their doses, and all statistical significances are the same as in Figure 1.
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5. Discussion
SCI leads to persistent pain and motor dysfunction, both of which lack effective 
therapeutics [105]. Therapeutic approaches that promote both neuroprotection and 
neuroregeneration are valuable for SCI therapies [52]. From the present discussed 
literature, the potential agents that have generated interest in SCI studies in the 
recent past include the multifactorial drugs minocycline, FK506, and CsA  
[18, 22, 52, 106].
In the present chapter also, the treated rats showed recovery in their hind limb 
reflexes rapidly regaining responses comparable with those of uninjured control rats 
(Figure 1). Although all drug-treated groups showed improved recovery in BBB and 
all behavioral activities, the best and the most significant recovery was observed 
with FK506 treatment. The drugs were effective in the order FK506 > minocycline > 
CsA throughout. Earlier studies have also used BBB scoring along with other behav-
ioral parameters and have shown significant behavioral functional outcome in the 
Figure 6. 
Levels of (A) thiobarbituric acid, (B) glutathione, and (C) myeloperoxidase activities in the injured spinal 
cord tissue of rats 29 days post-SCI and the effects of treatment with various drugs. Abbreviations, drugs used 
and their doses, and all statistical significances are the same as in Figure 1.
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SCI animals treated with FK506 [7, 22, 60, 67, 69, 70, 74, 76], minocycline  
[22, 28, 43–45], and CsA [18, 52, 53, 58, 61]. In addition to the therapeutic effects of 
the three drugs, it has been also suggested that the daily routine behavioral assess-
ment procedures may also assist the animals as equivalent to their exercises that help 
them to recover from SCI [107]. However, more studies are required to confirm this 
presumption. Additionally, no notable side effects were noted at the dosing regimen 
of the drugs (selected from the pilot studies) used in the present chapter. However, it 
has been suggested particularly for FK506 [63] that the therapeutic dosing regimen 
is a key factor that can affect efficacy as a neuroprotectant for CNS injuries.
FK506 has been reported by others also for being a potential therapy for SCI 
recovery through various mechanisms [7, 60, 63, 68, 108]. It is evidently proven 
that FK506 prevents the activation of NF-κB in microglia which reduces production 
of proinflammatory cytokines like TNF-a, IL-1b, and IL-6 in the SCI responses for 
effective recovery [7, 109]. Furthermore, it is suggested that inhibition of inflam-
matory reaction in SCI by FK506 could be due to its inhibitory action on decreasing 
the free radical formation and lipid peroxidation preventing calcineurin-mediated 
dephosphorylation of NOS activity in a Ca2+-dependent manner [77]. FK506 also 
enhances neurite outgrowth and improves functional recovery from SCI by stimu-
lating astrocytes to secrete epidermal growth factor (EGF) for neural repair [74].
CsA has also been reviewed and reported as a potent neuroprotectant for func-
tional recovery from SCI [5, 55]. The significant protective role of CsA has been 
reported for recovery from SCI through inhibiting the apoptosis of spinal cord 
cells [53], improving locomotor function [58], increasing mean arterial pressure 
[110], inhibiting NOS [56], diminishing demyelination and neuronal cell  
death [60], attenuating reactive astrocytosis due to injury improved neurologic 
outcome [50], and reducing pain [111].
Minocycline has also been reviewed recently for its effectiveness through 
multiple mechanisms for functional recovery from SCI [38]. The multiple targets 
that minocycline works for SCI functional recovery include upregulation of the 
protein VEGF and BDNF expressions; downregulation of protein p-38MAPK, 
proNGF, p75NTR, and RhoA expressions and suppressed caspase-3 activity [51]; 
and improved antioxidant activity through amelioration in oxidative stress in the 
SCI tissue [40].
Monoamines such as norepinephrine (NE), dopamine (DA), and serotonin 
(5-HT) can activate the spinal neurons involved in walking [112–114]. Thus, the 
decrease in the level of 5-HT and 5-HIAA in the SCI animals in the present chapter 
clearly indicates that SCI inevitably affects the normal functioning of these spinal 
neurotransmitters involved in locomotor function. SCI-injured animals treated 
with the drugs herein improved levels of 5-HT and 5-HIAA (Figure 5A–C, respec-
tively). Our present behavioral findings also showed an overall correlation and 
significant improvement in the functional deficits of the hind limbs after treatment 
with these drugs, indicating the presence of potential mechanisms of serotonergic 
agents in these drugs, as present in indorenate (5-methoxytryptamine, beta-methyl 
carboxylate hydrochloride), a 5-HT1A agonist that improved motor function in rats 
with chronic SCI [115].
The oxidant/antioxidant balance was clearly reflected by the increased level of 
TBARS (Figure 6A) and decreased level of GSH (Figure 6B) in the contused tissue 
of SCI control animals. However, treatment of SCI animals with the drugs inter-
fered with the formation of free radicals following traumatic SCI. The comparative 
behavioral restorative effects of these drugs in the formation of free radicals in 
injured SC were in the order of FK506 > minocycline > CsA.
Spinal cord injury in mice results in severe trauma characterized by edema and 
neutrophil infiltration (measured as an increase in myeloperoxidase activity), and 
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these neutrophils are thought to be involved in tissue injury through the release of 
various inflammatory mediators [116, 117]. The MPO levels in the present SCI ani-
mals were also significantly increased in the injured spinal cord tissue (Figure 6C). 
However, administration of minocycline, FK506, and CsA interfered significantly 
with the formation of MPO following traumatic SCI. The comparative restorative 
effects of these drugs in the formation of MPO in injured SC were in the order of 
FK506 > minocycline > CsA.
The pathophysiological events resulting from SCI are reported to involve free 
radical production; lipid peroxidation; excitotoxic molecules such as glutamate, 
eicosanoid, and prostaglandin production; protease activity; and intracellular 
increases in Ca2+ [118]. Furthermore, the primary auto-destructive event is initiated 
by the hydrolysis of fatty acids from membrane phospholipids, leading to cellular 
damage [119], and microglia becomes activated [120], which in turn may release 
neurotoxic molecules that further damage nearby neurons [121].
The hind limb functional deficits in the model of SCI (like the one as in the present 
chapter) are largely due to the loss of white matter axonal tracts [16, 122]. The white 
matter degeneration is caused by the primary injury (i.e., mechanical lesion), and 
there is also evidence that post-SCI demyelination caused by oligodendrocyte death/
malfunction contributes significantly to chronic SCI functional deficits [123, 124].
The secondary injury is reported to result from several proposed auto-destruc-
tive events, including reactive oxygen species-induced lipid peroxidation [125], 
activation of non-NMDA ionotropic glutamate receptors [126], and caspase-3 
activation [127, 128]. Secondary injury events include Na+ influx-mediated intra-
axonal Ca+ accumulation leading to proteinase activation, which destroys the 
cytoskeleton [16, 129], as well as the induction of oligodendroglial apoptosis with 
subsequent demyelination of the surviving axons [79, 130]. Lipid peroxidation is 
one of the main pathological mechanisms involved in secondary damage after SCI 
[79]. Another key factor in the secondary injury mechanism is Ca2+ ions. Following 
trauma or ischemia, Ca2+ influx plays an important role in the pathogenesis of 
neural injury [130, 131]. Many drugs, including steroids, gangliosides, ion chan-
nel blockers, antioxidants, and free radical scavengers, have mild therapeutic 
effectiveness in experimental spinal cord injury [74, 119]. Another mechanism to 
promote functional recovery after spinal cord injury is enhancing axonal regenera-
tion. Several strategies, including blocking myelin or glial scar inhibitors, delivery 
of neurotrophic factors, and cell transplantation, induce axonal outgrowth after 
experimental spinal cord injury. Among them, olfactory ensheathing cell grafts 
promote neuroprotection, axonal regeneration, and functional recovery after 
incomplete spinal cord injury [132, 133]. Furthermore, a regular enforced move-
ment activity may additionally help provide faster functional restoration and 
recovery after SCI [134].
Studies on combinatorial effects of CsA, minocycline, and FK506 in various 
combinations with each other or with other compounds may prove to be more 
effective in recovery from SCI. Earlier combined treatments like FK506 and NGF 
[76], FK506 and minocycline [22], FK506 and methylprednisolone [77], FK506 and 
RhoA inhibitor [76, 77], minocycline and bone marrow mesenchymal stem cells 
[51], and CsA with PEG-TAT [54] have all shown significant functional recovery 
from SCI as compared to these compounds individually.
6. Conclusions
From the overall literature review on the multifactorial effects of CsA, mino-
cycline, and FK506 and from the discussion of the present findings, it can be 
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concluded that the drugs CsA, minocycline, and FK506 induce good recovery from 
experimentally induced SCI in rats. However, these drugs significantly improve 
functional restoration, replenish 5-HT and 5-HIAA levels, and restore the oxidant/
antioxidant balance in the contused tissue after moderate SCI in rats in the order 
FK506 < minocycline < CsA. Furthermore, it is suggested that the present compres-
sive SCI model of rats could still serve as the most convenient model for therapeutic 
screenings of various drugs in search of ideal therapy for SCI. CsA, minocycline, 
and FK506 appear to have gained support in a multifactorial effective manner 
through ample research work and should be considered as ideal therapeutical agents 
for the treatment of acute SCI. These drugs should be supported for clinical trials 
with further studies and tests. Although FK506 appears to be the most promising 
among the three drugs, more work is needed to screen all three compounds as 
cocktails in various combinations with better expected outcomes in SCI recovery 
possibly due to their cumulative multifactorial beneficial effects.
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